CTIS2023-510405-18-00
Active, not recruiting
Phase 1
An open-label, phase 2 trial to evaluate the efficacy and safety of a single intravenous administration of GNT0003 (an adeno-associated viral vector expressing the UGT1A1 transgene) following imlifidase pre-treatment in adult participants with severe Crigler-Najjar syndrome requiring daily phototherapy and presenting pre-existing anti-AAV8 antibodies. - GNT-018-IDES
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Crigler-Najjar syndrome
- Sponsor
- Genethon
- Enrollment
- 3
- Status
- Active, not recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Male or female must be \= 18 years old or the legal age of consent in the jurisdiction in which the trial is taking place at the time of signing the informed consent., Participant with severe Crigler\-Najjar syndrome requiring \= 6 hours/ day of phototherapy., Participant with molecular confirmation of mutation in the UGT1A1 gene by DNA sequencing., Participant with detectable serum neutralizing antibodies against AAV8\., Participant with laboratory parameters value not clinically significant, as assessed by the investigator, and meeting the following criteria, a.Hematology, clinical chemistry and coagulation \= grade 1 (as per Common Terminology Criteria for Adverse Events \[CTCAE] criteria) (including but not limited to: activated partial thromboplastin time \=1\.5 x ULN, creatinine increased \=1\.5 x ULN, Platelet count decreased \=75,000/mm3, lymphocyte count increased \=20 000/mm3\). b.Alanine amino\-transferase (ALT), aspartate amino\-transferase (AST), gamma\-glutamyl transferase (GGT) \= grade 3 (as per CTCAE criteria: GGT, ALT and/or AST \=20\.0 x ULN if baseline was normal; \=20\.0 x baseline if baseline was abnormal)., Participants must agree to use a highly effective method of contraception from screening visit (V1\) to at least 48 weeks after start of IMP administration., Signed the study performance informed consent., Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
Exclusion Criteria
- •Participation in another interventional trial during this clinical trial, including investigational trial involving gene or cell therapeutics within 6 months prior to start of IMP administration and during the whole clinical trial; participation in non\-interventional registries or epidemiological studies is allowed., Participant presents or has a history of thrombotic thrombocytopenic purpura (TTP) or known familial history of TTP, Fibrosis score \= 3 (METAVIR) or 10 kPa based on: a)Fibrotest: performed within 12 months prior to screening visit 1\* Or b)FibroScan®: performed within 12 months prior to screening visit 1\* Or c)Liver biopsy taken within 24 months prior to screening visit 1\*, Participant with significant underlying liver disease., Presence of any other clinically significant illness., Participant with a history of major thrombotic events, active peripheral vascular disease, or proven hypercoagulable conditions., Participant with known hypersensitivity to imlifidase and its excipients., Contraindication to corticosteroids, sirolimus, imlifidase, or antihistamines., Treatment with any of the prior/concomitant therapies according to the time frames specified in the protocol. At any time : Gene therapy, Cell based therapy (e.g., stem cell transplantation), CRISPR/Cas9, or any other form of gene editing, imlifidase, Participant who underwent liver transplantation
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
An open label phase II trial to assess the efficacy and safety of a once daily oral dose of 50 mg BIBW 2992 in two cohorts of patients with HER2-negative metastatic breast cancer after failure of no more than two chemotherapy regimen -HER2-negative metastatic breast cancer after failure of no more than two chemotherapy regimen in two cohorts of patientsTwo Cohorts: Cohort A: Triple negative metastatic breast cancer, i.e. HER2-negative, estrogen-receptor-negative and progesterone receptor negativeCohort B:HER2-negative, estrogen-receptor-positive and/or progesterone-receptor positiveMedDRA version: 8.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2006-002018-36-BESCS Boehringer Ingelheim Comm.V60
Active, not recruiting
Not Applicable
An open label phase II trial to assess the efficacy and safety of a once daily oral dose of 50 mg BIBW 2992 in two cohorts of patients with HER2-negative metastatic breast cancer after failure of no more than two chemotherapy regimen -HER2-negative metastatic breast cancer after failure of no more than three chemotherapy regimen in two cohorts of patientsTwo Cohorts: Cohort A: Triple negative metastatic breast cancer, i.e. HER2-negative, estrogen-receptor-negative and progesterone receptor negativeCohort B:HER2-negative, estrogen-receptor-positive and/or progesterone-receptor positiveMedDRA version: 8.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2006-002018-36-DEBoehringer Ingelheim Pharma GmbH & Co. KG60
Active, not recruiting
Not Applicable
Phase II open-label study to investigate the efficacy and safety of PTK787/ZK222584 orally administered once daily or twice daily at a total daily dose of 1250 mg as second-line monotherapy in patients with Stage IIIB or Stage IV non-small-cell lung cancer (NSCLC) - Efficacy and safety of PTK787/ ZK 222584 1250 mg daily as 2nd line monotherapy in NSCLCon-Small Cell Lung Cancer (NSCLC)EUCTR2004-002290-22-DESchering AG110
Recruiting
Phase 2
An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects with Systemic SclerosisJPRN-jRCT2031210481ishiura Tomoyuki8
Active, not recruiting
Not Applicable
A Phase II, open-label study to assess the efficacy and tolerability of ZD6474 ZACTIMA 100 mg monotherapy in subjects with locally advanced or metastatic hereditary medullary thyroid cancer - NDocally advanced or metastatic hereditary medullary thyroid cancerMedDRA version: 9.1Level: LLTClassification code 10027105Term: Medullary thyroid cancerEUCTR2006-001354-28-ITASTRAZENECA15